

RESEARCH MONOGRAPH . COMPOUND PROFILE

LM22B-10

A triarylmethane neurotrophin mimetic identified through in silico screening of BDNF loop-domain pharmacophores, distinguished as the first small molecule to co-activate TrkB and TrkC receptors with preclinical efficacy across aging, Alzheimer's disease, Huntington's disease, traumatic brain injury, and corneal neuropathy models.

DOCUMENT	KDC-MN-1640
ISSUED	2026-05-22
REVISION	1.0
AUTHOR	Kodi <i>ac</i> biolabs Research
COMPOUND CLASS	Non-peptide triarylmethane small-molecule TrkB/TrkC neurotrophin receptor co-activator

RESEARCH USE ONLY

ABSTRACT

LM22B-10 (CAS 342777-54-2) is a non-peptide, blood-brain barrier permeant, triarylmethane small molecule that co-activates tropomyosin-related kinase B (TrkB) and tropomyosin-related kinase C (TrkC) neurotrophin receptors. It was identified by Yang, Massa, and Longo at Stanford University through in silico screening with a brain-derived neurotrophic factor (BDNF) loop-domain pharmacophore, coupled with low-throughput neuronal survival screening, and was first reported in *Neuropharmacology* in 2016. LM22B-10 is distinguished from prior small-molecule Trk ligands, which typically activate a single receptor subtype, by its dual activation of TrkB (EC₅₀ approximately 1.8 micromolar) and TrkC (EC₅₀ approximately 2.5 micromolar), producing neurotrophic activity with an EC₅₀ for neuronal survival of 200 to 300 nanomolar that exceeds the effects of recombinant BDNF and neurotrophin-3 (NT-3), individually and in combination, in hippocampal neuronal assays. The compound selectively activates TrkB and TrkC without engaging TrkA, and drives downstream Akt and ERK1/2 signaling in vitro and in vivo. Preclinical studies in aged mice demonstrated that LM22B-10 activates hippocampal and striatal TrkB and TrkC signaling, increases dendritic spine density, and supports neuronal integrity. In mouse models of Huntington's disease (R6/2 and Q140), the compound reduced intranuclear huntingtin aggregates, dendritic spine loss, microglial activation, and degeneration of medium spiny neurons while improving motor performance. In a rat controlled cortical impact model of traumatic brain injury, LM22B-10 at 10 mg/kg intraperitoneal reduced cortical cell death by approximately 59 percent and increased hippocampal doublecortin-positive

neurogenesis by approximately 65 percent, with concurrent improvement in spatial memory and anxiety-related behavior in injured animals. The compound has also demonstrated corneal nerve regeneration in both healthy and diabetic mouse wound models when delivered as topical eye drops. A derivative, PTX-BD10-2, was developed by Pharmatrophix with improved oral bioavailability and has demonstrated prevention of cholinergic neuron atrophy, restoration of hippocampal long-term potentiation, and normalization of synaptic function in late-stage Alzheimer's disease mouse models (hAPPLond/Swe) following chronic oral dosing. The mechanism of TrkB/TrkC activation by LM22B-10 is not without controversy. An independent validation study using microscale thermophoresis reported weak binding to the TrkB extracellular domain (K_d approximately 83 micromolar) and failure to induce TrkB, Akt, or ERK1/2 phosphorylation in conventional blotting assays, results that contrast with the original characterization. A 2025 review in the Journal of Medicinal Chemistry proposed that LM22B-10 and related putative Trk agonists may function as positive allosteric modulators binding the transmembrane domain rather than as classical orthosteric agonists. The discrepancy remains unresolved and constitutes a significant open question in the field. LM22B-10 has not entered clinical trials; it remains a preclinical research tool. This monograph reviews the chemistry, dual-receptor pharmacology, preclinical evidence base across disease models, the mechanistic controversy, sourcing and handling considerations, and a comparative assessment of five neurotrophin receptor ligands against LM22B-10 on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Common name: LM22B-10.

Alternate designations: C10 (abbreviation used in traumatic brain injury literature) [5].

Chemical Abstracts Service registry number: 342777-54-2 (free base).

International Union of Pure and Applied Chemistry name: 2-[4-[[4-[bis(2-hydroxyethyl)amino]phenyl]-(4-chlorophenyl)methyl]phenyl-(2-hydroxyethyl)amino]ethanol.

PubChem Compound Identifier: CID 542158.

No International Nonproprietary Name has been assigned. No marketed brand names exist. The compound is known exclusively by the laboratory designation LM22B-10, reflecting the Longo-Massa series nomenclature (LM) used by the Stanford laboratory that developed it. The related derivative with improved oral bioavailability is designated PTX-BD10-2 (Pharmatrophix designation) [4, 7].

1.2 Structural class and chemistry

LM22B-10 is a triarylmethane derivative. The structural core is a central sp³ methine carbon bearing three para-substituted phenyl groups: two phenyl rings carry para-bis(2-hydroxyethyl)amino (diethanolamine) substituents, and one phenyl ring carries a para-chloro substituent. The compound is therefore a 4-chlorophenyl-bis[4-(N,N-bis(2-hydroxyethyl)amino)phenyl]methane.

Molecular formula: C₂₇H₃₃ClN₂O₄ (free base).

Molecular weight: 485.02 g/mol (free base, average atomic masses).

Exact monoisotopic mass: 484.21 g/mol (free base).

Canonical

SMILES:

C1=CC(=CC=C1C(C2=CC=C(C=C2)N(CCO)CCO)C3=CC=C(C=C3)Cl)N(CCO)CCO.

Physical properties: White to off-white crystalline powder. Freely soluble in dimethyl sulfoxide (97 mg/mL, approximately 200 millimolar) and in ethanol (97 mg/mL). Insoluble in water. The water insolubility derives from the lipophilic tri-arylmethane core and the balance of four hydroxyl groups, which confer sufficient polarity for organic-solvent solubility but insufficient hydrophilicity for aqueous dissolution at physiologically relevant concentrations [1].

Computed physicochemical descriptors: Hydrogen bond donors: 4 (four hydroxyl groups). Hydrogen bond acceptors: 6 (two nitrogen atoms, four oxygen atoms). Rotatable bonds: 12. Topological polar surface area: approximately 73 angstroms squared. Calculated LogP (XLogP3): approximately 3.7, consistent with the compound's lipophilicity and water insolubility. These parameters place LM22B-10 outside the classical Lipinski rule-of-five boundaries for molecular weight (485 versus the 500 cutoff) and rotatable bonds (12 versus a preferred limit of 10), consistent with the poor oral bioavailability of the parent compound and the need for the PTX-BD10-2 derivative for oral applications [4, 7].

Stereochemistry: The central methine carbon carries two identical para-bis(2-hydroxyethyl)aminophenyl substituents; because two of the three aryl groups are chemically equivalent, the methine carbon is not a stereocenter and the compound does not exhibit optical isomerism. No chiral resolution is required and no stereochemical variants exist. The compound is supplied and characterized as a single constitutional isomer.

1.3 Synthesis

LM22B-10 was identified through a computational approach rather than through classical medicinal chemistry optimization. The Longo laboratory at Stanford University employed in silico screening against a pharmacophore model derived from the loop-2 subregion of the BDNF protein (the structural motif involved in TrkB receptor binding), coupled with low-throughput neuronal survival screening in mouse fetal hippocampal neurons, to identify candidate small molecules with neurotrophic activity [1, 2]. LM22B-10 emerged from this screen as a compound that, unlike the previously identified LM22A-4 series (which selectively activated TrkB), activated both TrkB and TrkC receptors.

The synthetic route to LM22B-10 has not been described in detail in the published literature. Based on the triarylmethane structure, the compound is accessible through electrophilic aromatic substitution chemistry. The most probable ret-

rosynthetic disconnection is condensation of 4-chlorobenzaldehyde with two equivalents of 4-(N,N-bis(2-hydroxyethyl)amino)aniline (or a protected derivative) under acid catalysis, yielding the triarylmethane through a Friedel-Crafts-type mechanism or a Baeyer-type condensation. The four free hydroxyl groups may require protection during the condensation step and subsequent deprotection. Purification by recrystallization from ethanol or by chromatography would yield the final product. Research-grade material is supplied by multiple chemical vendors at greater than 98 percent purity by high-performance liquid chromatography; one vendor lot (Selleckchem batch S676001) has been characterized at 99.91 percent purity by HPLC and nuclear magnetic resonance spectroscopy [1].

Industrial-scale synthesis has not been reported. The compound is available at milligram to gram quantities from research chemical suppliers. No salt forms have been reported; the compound is supplied and used exclusively as the free base.

2. Abstract

LM22B-10 (CAS 342777-54-2) is a non-peptide, blood-brain barrier permeant, triaryl-methane small molecule that co-activates tropomyosin-related kinase B (TrkB) and tropomyosin-related kinase C (TrkC) neurotrophin receptors, distinguished from prior small-molecule Trk ligands by its dual receptor activation profile. Identified at Stanford University through in silico screening of a BDNF loop-domain pharmacophore coupled with low-throughput neuronal survival screening, the compound was first reported in 2016 [1]. In hippocampal neuronal assays, LM22B-10 promoted cell survival (EC₅₀ 200 to 300 nanomolar) and accelerated neurite outgrowth to a degree exceeding that of recombinant BDNF and neurotrophin-3 individually or in combination [1]. The compound selectively activates TrkB (EC₅₀ approximately 1.8 micromolar) and TrkC (EC₅₀ approximately 2.5 micromolar) without engaging TrkA, and drives downstream Akt and ERK1/2 signaling in vitro and in vivo.

Preclinical efficacy has been demonstrated across multiple disease models: aging-associated hippocampal spine loss in mice, Huntington's disease (R6/2 and Q140 mouse models), traumatic brain injury in rats (controlled cortical impact), corneal nerve wounding in normal and diabetic mice, and Alzheimer's disease in hAPPLond/Swe transgenic mice (the latter using the orally bioavailable derivative PTX-BD10-2) [1, 3, 4, 5, 6, 7]. The mechanism of action has been contested by independent validation studies that found weak TrkB extracellular domain binding and failure to induce canonical Trk phosphorylation in blotting assays, raising the possibility that the compound functions through an allosteric rather than orthosteric mechanism [8, 9]. LM22B-10 has not entered clinical trials and remains a preclinical research tool.

3. Discovery and Development History

3.1 Origin of the Longo-Massa neurotrophin mimetic program

The neurotrophins, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), and nerve growth factor (NGF), are endogenous protein ligands that bind and activate the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA for NGF, TrkB for BDNF and NT-4, TrkC for NT-3) and the p75 neurotrophin receptor (p75NTR). Despite decades of evidence linking neurotrophin signaling deficits to neurodegeneration, the protein neurotrophins have poor pharmacokinetic properties: they do not cross the blood-brain barrier, are rapidly degraded in plasma, and require invasive delivery routes. The Longo laboratory at Stanford University and the Massa laboratory at the University of California, San Francisco / San Francisco Veterans Affairs Health Care System initiated a program to identify non-peptide small molecules that mimic neurotrophin receptor activation while possessing drug-like properties.

3.2 The LM22A series: TrkB-selective precursors

In 2010, Massa, Yang, and Longo reported the identification of LM22A-4 and related compounds through in silico screening against a pharmacophore derived from the loop-2 subregion b of BDNF (the structural motif SKGQL), a region implicated in TrkB binding [2]. The screen evaluated a virtual library of approximately one million commercially available small molecules. Candidate compounds were tested in a low-throughput neuronal survival assay in mouse fetal hippocampal neurons. LM22A-4, the lead compound, selectively activated TrkB (but not TrkA or TrkC), stimulated downstream Akt and ERK signaling, prevented neuronal degeneration in rodent models of traumatic brain injury, and exhibited blood-brain barrier penetration when administered intranasally at 0.22 mg/kg/day [2]. The LM22A compounds validated the approach of using neurotrophin loop-domain pharmacophores to identify receptor-selective small-molecule mimetics.

3.3 Identification of LM22B-10 as a dual TrkB/TrkC co-activator

Continuing the *in silico* screening and survival screening program, Yang, Massa, and Longo identified LM22B-10, which, unlike the LM22A series, bound to and activated both TrkB and TrkC [1]. The dual activation profile was a novel finding: no prior small-molecule Trk ligand had demonstrated co-activation of two Trk receptor subtypes. The discovery was first reported in 2016 in *Neuropharmacology*, with the principal finding that LM22B-10 increased cell survival and strongly accelerated neurite outgrowth, superseding the effects of BDNF, NT-3, or the two neurotrophins combined in hippocampal neuronal assays [1]. Additionally, the compound supported neurite outgrowth in the presence of inhibiting glycoproteins, a property not shared by the endogenous neurotrophins and potentially relevant to regenerative applications in the injured central nervous system.

3.4 Pharmatrophix and the PTX-BD10-2 derivative

Pharmatrophix, Inc. was founded in 2005 by Frank M. Longo to develop small-molecule neurotrophin receptor ligands for neurodegenerative diseases. The company's lead clinical program centers on LM11A-31, a small-molecule p75 neurotrophin receptor modulator that completed a Phase 2a randomized, placebo-controlled trial in mild to moderate Alzheimer's disease, with results published in *Nature Medicine* in 2024 [11]. For the TrkB/TrkC co-activation program, Pharmatrophix developed PTX-BD10-2, a derivative of LM22B-10 with improved oral bioavailability and blood-brain barrier penetration following oral administration [4]. PTX-BD10-2 retains equivalent efficacy to LM22B-10 in neuronal survival assays and activates identical downstream signaling pathways (PI3K/Akt, MAPK/ERK, PLCgamma/PKC) [7].

3.5 Current development status

As of the present monograph date, LM22B-10 and PTX-BD10-2 remain preclinical research compounds. No clinical trial registrations exist for either compound. The preclinical evidence base has expanded from the original 2016 characterization to include Huntington's disease (2023) [3], traumatic brain injury (2025) [5], corneal nerve regeneration (2022) [6], and two Alzheimer's disease studies with PTX-BD10-2

(2022 and 2024) [4, 7]. The clinical translation pathway depends on Pharmatrophix's development decisions and on resolution of the mechanistic controversy surrounding the compound class.

4. Molecular Pharmacology

4.1 TrkB receptor activation

TrkB (NTRK2) is a receptor tyrosine kinase activated by the endogenous neurotrophins BDNF and NT-4. LM22B-10 activates TrkB with an EC50 for receptor phosphorylation (TrkB Y817) of approximately 1.8 micromolar in cell-based assays [1]. The compound competitively inhibits BDNF binding to TrkB in TrkB-Fc fusion protein assays, demonstrating dose-dependent binding at concentrations of 250 to 2000 nanomolar [1]. Functional TrkB activation by LM22B-10 was confirmed by phosphorylation of TrkB tyrosine 817 in hippocampal neurons in vitro and in hippocampal and striatal tissue in vivo following intraperitoneal administration in mice [1].

The compound's mechanism of TrkB engagement has been characterized as involving the Trk extracellular domain: experiments using truncated receptor constructs demonstrated a requirement for the extracellular domain in the biological response [1]. However, this characterization has been challenged by independent validation (see Section 4.7).

4.2 TrkC receptor activation

TrkC (NTRK3) is a receptor tyrosine kinase activated by the endogenous neurotrophin NT-3. LM22B-10 activates TrkC with an EC50 for receptor phosphorylation (TrkC Y820) of approximately 2.5 micromolar [1]. The compound competitively inhibits NT-3 binding to TrkC in TrkC-Fc fusion protein assays [1]. The TrkC activation is of particular significance because it distinguishes LM22B-10 from the LM22A series (which activates TrkB but not TrkC) and from 7,8-dihydroxyflavone (which is reported to activate TrkB only).

In the preclinical Huntington's disease studies, the TrkC activation was specifically relevant because NT-3 levels and TrkC phosphorylation were reduced in the R6/2 mouse striatum, and LM22B-10 treatment restored both parameters [3].

4.3 Dual TrkB/TrkC co-activation and functional consequences

The simultaneous activation of TrkB and TrkC by a single small molecule produces biological effects that exceed those of activating either receptor alone. In hippocampal neuronal assays, LM22B-10 "increased cell survival and strongly accelerated neurite outgrowth, superseding the effects of brain-derived neurotrophic factor (BDNF), NT-3 or the two combined" [1]. The neurotrophic activity in survival assays shows an EC₅₀ of 200 to 300 nanomolar, approximately an order of magnitude lower than the individual receptor-activation EC₅₀ values, suggesting that co-activation of both Trk receptors produces a cooperative effect on downstream survival signaling [1].

The compound's survival-promoting activity was quantified as 53 plus or minus 7.2 percent above BDNF and 91 plus or minus 8.6 percent above NT-3 at optimal concentrations [1]. This supra-neurotrophin effect is a key distinguishing feature and suggests that dual Trk co-activation recruits signaling nodes or synergistic pathway interactions not fully engaged by either neurotrophin alone.

Additionally, LM22B-10 supported substantial early neurite outgrowth in the presence of inhibiting glycoproteins (such as myelin-associated glycoprotein and Nogo-A), a property not shared by the endogenous neurotrophins [1]. This glycoprotein-resistant outgrowth is potentially significant for applications in central nervous system injury, where myelin-derived growth inhibitors limit axonal regeneration.

4.4 Downstream signaling

LM22B-10 activates the canonical Trk receptor downstream signaling cascades: phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK1/2) [1]. In vivo, intraperitoneal administration at 0.5 mg/kg in mice was sufficient to activate Akt and ERK1/2 in hippocampal and striatal tissue, and 50 mg/kg intraperitoneal elevated TrkB Y817 and TrkC Y820 phosphorylation [1]. The derivative PTX-BD10-2 activates the same pathways (PI3K/Akt, MAPK/ERK, PLCgamma/PKC) following oral administration [7].

In hippocampal slice electrophysiology from Alzheimer's disease model mice, acute bath application of PTX-BD10-2 at 100 nanomolar normalized phosphorylation of Akt, calcium-calmodulin-dependent kinase II (CaMKII), and GluA1 subunit-containing AMPA-type glutamate receptors, enhanced activity-dependent recruitment of synaptic proteins, and restored long-term potentiation (LTP) deficits [7]. Chronic oral treatment at 50 mg/kg for three months produced LTP magnitude of 151 plus or minus 21 percent of baseline (compared with 111 plus or minus 8 percent in vehicle-treated APP mice), restored PSD-95 levels from a 31 percent reduction, and increased excitatory synapse number (VGlut1/PSD-95 colocalization) [7].

Transcriptomic analysis of hippocampal slices from PTX-BD10-2-treated Alzheimer's model mice revealed normalized activity-dependent transcription of synaptic genes, restoration of LTP-dependent downregulation of synaptic signaling gene modules, and upregulation of complement pathway and immune-associated genes in microglia [7]. These transcriptomic effects suggest that TrkB/TrkC activation by the compound engages gene expression programs associated with synaptic plasticity maintenance.

4.5 p75NTR interactions

The p75 neurotrophin receptor (p75NTR), a member of the tumor necrosis factor receptor superfamily, modulates neurotrophin signaling through interactions with Trk receptors and through independent pro-apoptotic and degenerative signaling. The original characterization of LM22B-10 reported "differential interactions with p75(NTR)" that contributed to the compound's mechanism, but more recent studies from the same group describe the compound's activity as occurring without interaction with p75NTR [1, 7]. The precise relationship between LM22B-10 and p75NTR remains incompletely characterized.

4.6 Selectivity and off-target pharmacology

LM22B-10 is selective for TrkB and TrkC over TrkA: no activation of TrkA phosphorylation was observed in primary hippocampal neurons at concentrations that activated TrkB and TrkC [1]. In a broad pharmacological selectivity screen (57-receptor panel), LM22B-10 at 10 micromolar produced greater than 50 percent inhibition of 5-HT_{5A} serotonin receptors and the dopamine transporter [8]. These off-target interactions occur at concentrations substantially above the neurotrophic EC₅₀ (200 to 300 nanomolar) and above the TrkB/TrkC activation EC₅₀ (1.8 to 2.5 micromolar),

but are within the range of concentrations used in some in vitro experiments (1 to 10 micromolar) and potentially at in vivo concentrations achieved with high-dose intraperitoneal administration (50 mg/kg). Investigators should consider these off-target activities when interpreting mechanism-of-action studies at high concentrations.

4.7 Mechanistic controversy: direct agonism versus allosteric modulation

The characterization of LM22B-10 as a TrkB/TrkC receptor agonist has been challenged by independent validation studies. Pankiewicz, Matloka, and colleagues (2021) screened approximately 1000 compounds, including LM22B-10 and multiple other putative small-molecule Trk agonists, using microscale thermophoresis (MST) binding assays, ligand-induced TrkB dimerization assays, enzyme-linked fixed-cell immunoassays for TrkB phosphorylation (Tyr706/707), and Western blotting for downstream signaling (Akt, ERK1/2) [8]. LM22B-10 bound the isolated TrkB extracellular domain with a K_d of approximately 83 micromolar by MST, substantially weaker than expected for a primary agonist. The compound did not induce TrkB dimerization and did not induce phosphorylation of TrkB, Akt, or ERK1/2 in the assay systems employed [8].

The same study found that multiple other putative small-molecule Trk agonists, including 7,8-dihydroxyflavone, LM22A-4, amitriptyline, N-acetyl serotonin, deoxygedunin, and deprenyl, also failed to demonstrate genuine TrkB agonism in their assay panel [8]. DMAQ-B1 (demethylasterriquinone B1) was the only compound to induce TrkB phosphorylation, but its downstream effects were independent of TrkB kinase activity (not suppressed by the Trk inhibitor K252a), suggesting a non-canonical mechanism [8].

A 2025 review in the Journal of Medicinal Chemistry by Thompson, Sefiani, and Burgess discussed these findings and proposed that LM22B-10 and related compounds may function as positive allosteric modulators (PAMs) binding the Trk transmembrane domain rather than as classical orthosteric agonists binding the extracellular domain [9]. The rationale is that these compounds share amphipathic or hydrophobic structural features that favor interaction with lipophilic transmembrane regions, particularly the cholesterol recognition amino acid consensus (CRAC/CARC) domain identified in TrkB [9]. This mechanism would parallel the re-

cently characterized binding of psychedelic compounds (psilocin, lysergic acid diethylamide) to the TrkB transmembrane domain, where they enhance BDNF-induced signaling without direct agonism [9].

Several explanations for the discrepancy between the original Longo laboratory findings and the Pankiewicz validation have been proposed: differences in cell types (primary hippocampal neurons versus transfected non-neuronal cell lines), differences in endogenous neurotrophin background (primary neurons secrete low levels of BDNF and NT-3 that could provide a substrate for allosteric modulation), differences in phosphorylation kinetics and antibody sensitivity, and differences in the critical assay variable of membrane cholesterol composition [9]. The discrepancy is unresolved as of the present date.

The *in vivo* efficacy data across multiple disease models from the Longo laboratory and collaborators (aging, Huntington's disease, traumatic brain injury, corneal nerve regeneration, Alzheimer's disease) demonstrate consistent biological activity of LM22B-10 and PTX-BD10-2 in living systems [1, 3, 4, 5, 6, 7]. Whether this activity proceeds through direct TrkB/TrkC orthosteric agonism, transmembrane allosteric modulation, or an indirect mechanism remains an important open question. Investigators should be aware of this controversy when interpreting mechanism-of-action claims and when designing experiments intended to isolate the TrkB/TrkC contribution to the compound's effects.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption and bioavailability

Formal pharmacokinetic studies of LM22B-10 have not been published as stand-alone investigations. The available pharmacokinetic information derives from in vivo efficacy studies and from the development of the PTX-BD10-2 derivative.

LM22B-10 itself has poor oral bioavailability. The development of PTX-BD10-2 was explicitly motivated by the need for "improved oral bioavailability" relative to the parent compound [4]. The structural modification(s) that distinguish PTX-BD10-2 from LM22B-10 have not been publicly disclosed, but the derivative demonstrates blood-brain barrier penetration following oral administration and a plasma half-life of approximately 2 hours in mice [7].

5.2 Distribution and blood-brain barrier penetration

LM22B-10 is described as a "blood-brain barrier permeant small-molecule TrkB/TrkC co-activator" when delivered by parenteral routes [5]. Intraperitoneal administration at 0.5 to 50 mg/kg in mice produces measurable activation of TrkB, TrkC, Akt, and ERK1/2 signaling in hippocampal and striatal tissue, confirming central nervous system penetration [1]. The compound's lipophilic triarylmethane core and moderate molecular weight (485 g/mol) are consistent with passive blood-brain barrier permeation.

Volume of distribution, plasma protein binding, and tissue partition coefficients have not been formally reported. The water insolubility of the compound (insoluble in aqueous media) and its high solubility in DMSO (97 mg/mL) and ethanol (97 mg/mL) indicate a lipophilic physicochemical profile.

5.3 Metabolism

No cytochrome P450 metabolism studies, microsomal stability studies, or metabolite identification studies have been published for LM22B-10. The triarylmethane structural class is susceptible to hepatic oxidation at the methine carbon and to conjugation of the diethanolamine hydroxyl groups, but the specific metabolic pathways and responsible CYP isoforms are unknown.

Pankiewicz et al. (2021) reported chemical stability data for several putative Trk agonists in their screening campaign but did not report specific stability data for LM22B-10 [8]. Investigators requiring metabolic stability information should conduct their own in vitro microsomal assays.

5.4 Routes of administration

Three principal routes have been used in published studies:

Intraperitoneal: The most common research route. LM22B-10 is dissolved in Cremophor/phosphate-buffered saline vehicle and administered at doses of 0.5 to 50 mg/kg in mice and 10 mg/kg in rats [1, 5]. Central nervous system effects (Trk activation, dendritic spine changes, behavioral outcomes) have been consistently demonstrated by this route.

Intranasal: Used in aged mouse studies and in the Huntington's disease studies, often in combination with intraperitoneal administration [1, 3]. The intranasal route provides direct access to the central nervous system via the olfactory and trigeminal pathways, bypassing first-pass hepatic metabolism.

Topical ophthalmic: LM22B-10 has been administered as eye drops in corneal nerve regeneration studies in mice [6].

Oral (PTX-BD10-2): The derivative PTX-BD10-2 is administered by oral gavage at 50 mg/kg in hydroxypropyl-beta-cyclodextrin vehicle, once daily, in mouse studies [7]. This route produces measurable central nervous system effects on hippocampal electrophysiology and synaptic markers.

5.5 Dosing parameters across published studies

The following consolidation of dosing parameters used across the published pre-clinical literature is provided to assist investigators in experimental design:

In the aged mouse study, Yang et al. (2016) used 0.5 mg/kg and 50 mg/kg intraperitoneal, with both doses producing measurable central nervous system target engagement (TrkB/TrkC phosphorylation, Akt/ERK activation), indicating a broad effective dose range [1]. In the Huntington's disease studies, Simmons et al. (2023) used concomitant intranasal and intraperitoneal routes; exact doses were not specified in the abstract [3]. In the traumatic brain injury study, Shi et al. (2025) used 10 mg/kg intraperitoneal, daily, beginning immediately post-injury, in Cremophor/PBS vehicle, with treatment continuing for up to 14 days [5]. In the corneal nerve regeneration study, Cui et al. (2022) used topical ophthalmic drops; concentration and frequency were not detailed in the abstract [6]. For PTX-BD10-2, Latif-Hernandez et al. (2024) used 50 mg/kg oral gavage in hydroxypropyl-beta-cyclodextrin vehicle, once daily, five days per week, for three months [7].

No dose-finding, dose-ranging, or maximum tolerated dose studies have been published for either LM22B-10 or PTX-BD10-2. The selection of doses in published studies appears to have been based on preliminary pilot data not included in the published reports.

5.6 Human pharmacokinetics

No human pharmacokinetic data exist for LM22B-10 or PTX-BD10-2. The compounds have not entered clinical trials. No formal absorption, distribution, metabolism, and excretion (ADME) characterization has been published in any species. The following pharmacokinetic parameters remain entirely unknown: oral bioavailability (quantitative), volume of distribution, plasma protein binding, renal clearance, hepatic clearance, CYP isoform substrate status, CYP inhibition/induction potential, and active metabolite formation. Investigators requiring human pharmacokinetic projections should extrapolate from the mouse data with appropriate allometric scaling and should treat any such projections as preliminary estimates pending formal characterization.

6. Preclinical Pharmacology

6.1 In vitro neurotrophic activity

The foundational in vitro characterization of LM22B-10 was reported by Yang et al. (2016) in mouse fetal hippocampal neurons [1]. The compound increased neuronal survival with an EC₅₀ of 200 to 300 nanomolar, with maximal activity exceeding that of recombinant BDNF by 53 plus or minus 7.2 percent and that of recombinant NT-3 by 91 plus or minus 8.6 percent [1]. Notably, LM22B-10 at optimal concentrations produced greater neurotrophic activity than the combination of BDNF and NT-3 together, suggesting cooperative signaling through the dual TrkB/TrkC mechanism.

LM22B-10 also strongly accelerated neurite outgrowth in hippocampal neurons and, uniquely among tested agents, supported substantial early neurite outgrowth in the presence of myelin-derived inhibiting glycoproteins [1]. This glycoprotein-resistant outgrowth phenotype has potential translational significance for central nervous system injury and regeneration, where myelin debris inhibits axonal regrowth.

In neural progenitor cell cultures, LM22B-10 at 1 micromolar significantly increased proliferation, survival, and enhanced differentiation, with 22 plus or minus 6.2 percent of doublecortin-positive (DCX+) cells co-expressing TrkB and 9.8 plus or minus 5.8 percent co-expressing TrkC in the hippocampal subgranular zone [5].

In dorsal root ganglion (DRG) and corneal stromal cell co-culture three-dimensional models, LM22B-10 promoted nerve bundle extension throughout collagen scaffolds within 14 days through activation of the ERK-CREB signaling pathway [6]. The mechanism involved NT-3-mediated activation of ERK-CREB in DRG neurons and IL-6-mediated upregulation of anti-apoptotic genes in stromal cells [6].

6.2 Aged mouse studies

In aged mice, LM22B-10 administered by combined intraperitoneal (50 mg/kg) and intranasal routes activated hippocampal and striatal TrkB and TrkC receptor phosphorylation, stimulated downstream Akt and ERK1/2 signaling, and increased hip-

pocampal dendritic spine density [1]. These findings demonstrate that the compound retains in vivo neurotrophic activity in the aging central nervous system, where endogenous neurotrophin levels are reduced and synaptic integrity is declining.

At a lower dose of 0.5 mg/kg intraperitoneal, LM22B-10 was sufficient to activate TrkB, TrkC, Akt, and ERK signaling in hippocampal and striatal tissue [1], indicating that central nervous system target engagement occurs across a broad dose range. The dose-response relationship between 0.5 and 50 mg/kg has not been formally characterized.

6.3 Huntington's disease models

Simmons, Belichenko, and Longo (2023) evaluated LM22B-10 in two mouse models of Huntington's disease: the R6/2 transgenic model (expressing exon 1 of human huntingtin with approximately 150 CAG repeats) and the Q140 knock-in model (expressing full-length murine huntingtin with approximately 140 CAG repeats) [3]. LM22B-10 was delivered by concomitant intranasal and intraperitoneal routes.

The R6/2 striatum exhibited reduced NT-3 levels, reduced TrkB and TrkC phosphorylation, and reduced Akt signaling relative to wild-type controls. LM22B-10 treatment counteracted each of these deficits [3]. Additionally, LM22B-10 reduced the size of intranuclear huntingtin aggregates in the striatum, reduced dendritic spine loss, reduced microglial activation (a marker of neuroinflammation), and reduced degeneration of two vulnerable striatal neuron populations: DARPP-32-expressing medium spiny neurons (the principal projection neurons of the striatum, which are the primary cell type lost in Huntington's disease) and parvalbumin-expressing interneurons [3].

Both the R6/2 and Q140 models showed improved motor performance following LM22B-10 treatment [3]. The motor improvement is consistent with the neuroprotection of striatal projection neurons observed histologically.

These findings support the hypothesis that dual TrkB/TrkC activation can address the neurotrophin signaling deficits that contribute to Huntington's disease pathogenesis. The study is the first demonstration of pharmacological TrkB/TrkC co-activation as a therapeutic strategy in Huntington's disease models.

6.4 Traumatic brain injury

Shi, Yang, Li, Zhong, Longo, and Massa (2025) evaluated LM22B-10 in a rat controlled cortical impact (CCI) model of traumatic brain injury [5]. Male Sprague-Dawley rats (7 to 8 weeks old) received moderate CCI injury (2.5 mm impactor tip, 1.5 m/s velocity, 2.5 mm depth, 120 ms dwell time) and were treated with LM22B-10 at 10 mg/kg intraperitoneal, administered daily beginning immediately after injury.

Cell death: LM22B-10 treatment produced a 58.6 plus or minus 8.9 percent reduction in Fluoro-Jade C-positive (degenerating) cells in the injured cortex at 1 day post-injury compared with vehicle-treated injured cortex ($p = 0.002$) [5].

Neurogenesis: In the hippocampal subgranular zone, LM22B-10 increased DCX-positive (immature neuron) cells by approximately 65.4 plus or minus 7.2 percent relative to vehicle in TBI animals. DCX/BrdU double-positive cells (newly proliferated immature neurons) increased by 106 plus or minus 4.8 percent with LM22B-10 in both sham and TBI groups [5].

Behavioral outcomes: In the Barnes maze (spatial memory), TBI animals treated with LM22B-10 showed significantly improved learning rates relative to vehicle-treated TBI animals ($p < 0.05$). In the open-field test (anxiety), TBI-induced reduction in center entries was restored to normal levels with LM22B-10 treatment ($p = 0.024$). In the elevated plus maze (anxiety), TBI animals showed improved open-arm entries with LM22B-10 relative to vehicle [5].

Bimodal response: A notable and cautionary finding was that LM22B-10 produced opposite effects in sham (uninjured) animals: decreased learning rate in the Barnes maze ($p < 0.01$) and increased anxiety-like behavior in the elevated plus maze ($p = 0.008$) [5]. The authors interpreted this as suggesting that "excess neurotrophic activity may be detrimental in uninjured animals but compensatory after injury" [5]. This bimodal response has implications for dosing strategy and for the safety profile of neurotrophic agents in non-pathological contexts.

6.5 Corneal nerve regeneration

Cui, Chen, Tang, and colleagues (2022) evaluated LM22B-10 as a topical ophthalmic agent for corneal nerve regeneration in mouse models of corneal wounding [6]. The study constructed a dorsal root ganglion-corneal stromal cell (DRG-CSC) three-di-

mensional co-culture model and demonstrated that LM22B-10 promoted nerve bundle extension via activation of the ERK-CREB signaling pathway through TrkB/TrkC receptors [6].

In vivo, LM22B-10 administered as eye drops to both normal and diabetic mice with corneal wounds significantly improved corneal epithelial healing speed, corneal sensitivity, and corneal nerve density [6]. Diabetic corneal neuropathy is a significant clinical problem with limited therapeutic options, and the demonstration of efficacy in diabetic mice is relevant to potential translational applications. The study represents the first application of a small-molecule TrkB/TrkC co-activator to peripheral nerve regeneration in the eye.

6.6 Alzheimer's disease models (PTX-BD10-2)

Two studies have evaluated PTX-BD10-2, the orally bioavailable derivative of LM22B-10, in the hAPPLond/Swe (APPL/S) transgenic mouse model of Alzheimer's disease.

Gonzalez, McHugh, Yang, Syriani, Longo, and Simmons (2022) administered PTX-BD10-2 orally to symptomatic APPL/S mice at a disease stage when amyloid and cholinergic pathology were already established, paralleling the clinical context in which most Alzheimer's patients initiate treatment [4]. PTX-BD10-2 restored cholinergic neurite integrity in the nucleus basalis of Meynert and vertical diagonal band (the principal cholinergic nuclei that degenerate in Alzheimer's disease), reduced neuronal atrophy, reduced cholinergic dystrophy in basal forebrain target regions, and reduced tau pathology [4]. In iPSC-derived human cholinergic neurons exposed to amyloid-beta, a derivative of LM22B-10 increased neuronal survival [4].

Latif-Hernandez, Yang, Butler, and colleagues (2024) conducted a more extensive evaluation, administering PTX-BD10-2 at 50 mg/kg by oral gavage, once daily, five days per week, for three months, beginning at 13 months of age in APPL/S mice (assessed at 16 months) [7]. The study employed hippocampal slice electrophysiology, behavioral testing, immunofluorescence, immunoblotting, and RNA sequencing. PTX-BD10-2 treatment improved memory deficits, restored hippocampal long-term potentiation (LTP magnitude: 151 plus or minus 21 percent of baseline versus 111 plus or minus 8 percent in APP-vehicle mice at 120 minutes post-stimulation), normalized phosphorylation of Akt, CaMKII, and GluA1 AMPA receptor subunits, enhanced activity-dependent synaptic protein recruitment, and increased excitatory synapse number [7].

Importantly, PTX-BD10-2 treatment did not significantly reduce amyloid-beta plaque load [7]. The compound's mechanism of action is therefore not plaque-clearing but rather synaptic-protective and function-restorative, operating downstream of or parallel to amyloid accumulation. Transcriptomic analysis revealed that PTX-BD10-2 normalized activity-dependent gene transcription disrupted by amyloid pathology and modulated complement pathway and immune-associated gene expression in microglia [7].

7. Clinical Evidence Base

This section is provided in compliance with the monograph template. Investigators should note that the following summary documents the absence, rather than the presence, of human clinical data for LM22B-10 and PTX-BD10-2.

7.1 Regulatory and clinical trial status

LM22B-10 and PTX-BD10-2 have not entered clinical trials. No Investigational New Drug (IND) application, Clinical Trial Application (CTA), or equivalent regulatory submission has been publicly reported for either compound. No NCT registration exists on ClinicalTrials.gov for either compound as of the present monograph date.

7.2 Related clinical program: LM11A-31

The closest clinical analog from the same research program is LM11A-31, a small-molecule p75 neurotrophin receptor modulator developed by Pharmatrophix. LM11A-31 targets a different receptor (p75NTR rather than TrkB/TrkC) and operates through a different mechanism (modulation of p75NTR degenerative signaling rather than activation of Trk neurotrophic signaling). A Phase 2a randomized, placebo-controlled trial (NCT03069014) of LM11A-31 in 242 patients with mild to moderate Alzheimer's disease was completed and published in Nature Medicine in 2024 [11]. The trial met its primary endpoint for safety and tolerability; prespecified secondary and exploratory endpoints in structural MRI, FDG-PET, and cerebrospinal fluid biomarkers showed significant drug-placebo differences consistent with slowing of pathophysiological progression, though no significant cognitive benefit was observed [11]. This trial validates the broader Pharmatrophix neurotrophin receptor platform at the clinical level and may inform future development decisions for the TrkB/TrkC program.

7.3 Translational considerations

The absence of clinical data represents a significant limitation of the LM22B-10 evidence base. Investigators considering this compound for research should be aware that: (a) all efficacy data derive from rodent models with incomplete translation to

human neurological disease; (b) no human safety, tolerability, or pharmacokinetic data exist; (c) the mechanistic controversy regarding direct Trk agonism versus allosteric modulation (see Section 4.7) has implications for the rational design of clinical dose-finding studies; and (d) the oral bioavailability limitation of the parent compound necessitates the use of the PTX-BD10-2 derivative for any oral-administration clinical program.

8. Sourcing and Quality Verification

LM22B-10 is a research-grade compound available from multiple chemical and pharmaceutical research suppliers. It is not a registered medicine in any jurisdiction and is not available in pharmaceutical-grade formulations.

Suppliers: The compound is available from Tocris Bioscience (catalog number 6037), Selleckchem, Cayman Chemical (catalog number 29037), MedChemExpress, InvivoChem, TargetMol, BOC Sciences, and other research chemical vendors. Supply is in milligram to multi-gram quantities as the free base.

Purity: Research-grade LM22B-10 is typically supplied at greater than 98 percent purity by HPLC. One vendor lot (Selleckchem batch S676001) has been characterized at 99.91 percent purity by HPLC and nuclear magnetic resonance spectroscopy. Vendors provide certificates of analysis with HPLC chromatograms, mass spectrometry confirmation of molecular weight, and nuclear magnetic resonance spectral data.

Identity verification: Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (485.02 plus or minus 0.02 for the protonated molecular ion $[M+H]^+$, or 484.21 plus or minus 0.01 for the monoisotopic mass)
- Nuclear magnetic resonance spectroscopy (1H NMR and ^{13}C NMR) with comparison to published or vendor-supplied reference spectra
- Karl Fischer or thermogravimetric analysis for residual water (the compound is hygroscopic)

Common impurities: The triarylmethane synthesis may produce residual aldehyde starting material (4-chlorobenzaldehyde), incomplete condensation products (diarylmethane intermediates), and solvent residues. Reverse-phase HPLC with UV detection is the standard analytical method for detection of these impurities.

Stability indicators: Vendors report the compound as stable in powder form at minus 20 degrees Celsius for 3 years and at 4 degrees Celsius for 2 years. No degradation products have been characterized in the literature. Pankiewicz et al. (2021) evaluated chemical stability for compounds in their Trk agonist screen and reported that DMAQ-B1 showed 12.76 percent degradation under their standard conditions [8]; equivalent stability data for LM22B-10 were not reported in that publication, but the compound's triarylmethane structure is expected to be more chemically stable than the quinone-containing DMAQ-B1.

Recommended verification workflow: On receipt of a new batch: (a) confirm molecular weight by LC-MS; (b) verify purity by HPLC with UV detection at 254 nm; (c) compare ¹H NMR spectrum to vendor reference or published data; (d) prepare a DMSO stock, verify dissolution visually; (e) archive certificate of analysis with lot number for future cross-reference in publications.

Third-party analytical confirmation is recommended for mechanism-of-action studies and dose-response investigations where compound integrity is critical. The research-grade LM22B-10 market is established but small; lot-to-lot variability is possible and on-receipt analytical verification is appropriate.

9. Reconstitution and Handling

LM22B-10 free base is insoluble in water. Stock solutions must be prepared in organic solvents.

Stock solution preparation: Dissolve in dimethyl sulfoxide (DMSO) at up to 97 mg/mL (approximately 200 millimolar) for in vitro applications. For in vivo intraperitoneal injection, dissolve in Cremophor EL/phosphate-buffered saline vehicle [5] or in DMSO followed by dilution into an appropriate aqueous vehicle (note: DMSO concentration in the final injectable solution should be minimized to reduce vehicle toxicity). For in vitro applications, the compound may be dissolved in 0.04 N hydrochloric acid and diluted 1:10,000 or greater into culture medium [5].

Storage: The powder form is stable at minus 20 degrees Celsius for up to 3 years. Stock solutions in DMSO are stable at minus 80 degrees Celsius for up to 1 year and at minus 20 degrees Celsius for up to 1 month. Stored stock solutions at 4 degrees Celsius in powder form are stable for up to 2 years. Light protection is recommended but not strictly required.

Aliquoting: Single-use aliquoting of DMSO stock solutions is recommended to avoid repeated freeze-thaw cycles. While formal freeze-thaw stability data have not been published for LM22B-10, the triarylmethane chemical class is generally stable through multiple freeze-thaw cycles in DMSO.

For topical ophthalmic use: In the corneal nerve regeneration studies, LM22B-10 was formulated as eye drops [6]. The specific ophthalmic vehicle and concentration have not been described in detail in the abstract; investigators intending to replicate this route should consult the full methods of Cui et al. (2022).

For oral use (PTX-BD10-2): The derivative PTX-BD10-2 is dissolved in hydroxypropyl-beta-cyclodextrin (HPCD) vehicle for oral gavage at 50 mg/kg in a volume of 10 mL/kg [7]. HPCD is a standard pharmaceutical excipient for enhancing the solubility and oral bioavailability of lipophilic compounds.

10. Stack Interactions and Combinations

10.1 Pharmacokinetic interactions

No formal drug-drug interaction studies have been conducted for LM22B-10. The CYP substrate, inhibitor, and inducer status of the compound is unknown. The triarylmethane structural class does not have a well-characterized metabolic profile, and investigators conducting combination research should consider the possibility of unanticipated metabolic interactions.

10.2 Pharmacodynamic interactions through Trk signaling

LM22B-10 activates PI3K/Akt and MAPK/ERK signaling cascades. Concurrent administration with other compounds that modulate these pathways could produce additive, synergistic, or antagonistic effects:

Other TrkB agonists or modulators: Concurrent use with 7,8-dihydroxyflavone, LM22A-4, or other putative TrkB agonists would be expected to produce additive TrkB-related signaling. Whether this produces additive neurotrophic benefit or drives receptor desensitization and signal attenuation is unknown and would require experimental evaluation.

p75NTR modulators: Concurrent use with LM11A-31 (the p75NTR small-molecule modulator from the same research program) could produce complementary effects: LM22B-10 activating Trk neurotrophic signaling while LM11A-31 inhibits p75NTR degenerative signaling. This combination has not been studied but represents a rational mechanistic pairing.

Acetylcholinesterase inhibitors: Concurrent use with donepezil, rivastigmine, or galantamine is plausible for cognitive research applications. The PTX-BD10-2 Alzheimer's disease studies did not include cholinesterase inhibitor comparators; the combination has not been characterized.

NMDA receptor modulators: Concurrent use with memantine is plausible. No interaction data exist for this combination. BDNF-TrkB signaling modulates NMDA receptor subunit expression and trafficking; pharmacological TrkB/TrkC co-activation by LM22B-10 could therefore alter the density and subunit composition of NMDA receptors, modifying the pharmacodynamic profile of memantine or other NMDA modulators.

Growth factor receptor inhibitors: Concurrent use with receptor tyrosine kinase inhibitors used in oncology (e.g., Trk inhibitors larotrectinib, entrectinib) would be expected to antagonize LM22B-10's TrkB/TrkC activation. This combination is pharmacologically contradictory and would not typically be employed experimentally, but investigators should be aware that residual Trk inhibitor exposure from prior dosing periods could confound subsequent LM22B-10 experiments.

Lithium and GSK-3beta modulators: Lithium inhibits glycogen synthase kinase-3beta (GSK-3beta), which lies downstream of the PI3K/Akt pathway activated by LM22B-10. Concurrent lithium and LM22B-10 could produce additive effects on GSK-3beta inhibition and its downstream targets (including tau phosphorylation and glycogen metabolism). This interaction is theoretically relevant in Alzheimer's disease research contexts where both agents might be of interest.

10.3 Off-target interactions

The 5-HT_{2A} serotonin receptor inhibition and dopamine transporter inhibition observed at 10 micromolar in selectivity screening could produce pharmacodynamic interactions with serotonergic agents (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, triptans) and with dopaminergic agents (levodopa, dopamine agonists, antipsychotics) at high concentrations. These interactions are unlikely to be clinically relevant at the nanomolar-to-low-micromolar concentrations at which the compound exerts neurotrophic activity, but should be considered in high-dose in vitro experimental designs.

10.4 Vehicle interactions

The requirement for DMSO or Cremophor vehicles in in vitro and in vivo applications introduces vehicle-specific toxicity considerations. DMSO at concentrations above 0.1 percent can affect cell membrane fluidity and gene expression in sensi-

tive cell lines. Cremophor EL has known dose-dependent toxicity in rodents and hypersensitivity potential. Appropriate vehicle controls are essential in all experimental designs.

11. Adverse Events and Safety Signal

11.1 Preclinical safety overview

No formal toxicology studies (acute, subacute, or chronic) have been published for LM22B-10 or PTX-BD10-2. The safety information available derives exclusively from the adverse event and behavioral monitoring conducted within the published efficacy studies.

11.2 Bimodal neurotrophic response in uninjured animals

The most significant safety-relevant finding is the bimodal behavioral response reported in the traumatic brain injury study [5]. LM22B-10 at 10 mg/kg intraperitoneal in uninjured (sham) rats produced: decreased learning rate in the Barnes maze spatial memory task ($p < 0.01$) and decreased frequency of entry into open/bright arms in the elevated plus maze ($p = 0.008$), suggesting increased anxiety-like behavior [5]. These effects were opposite to the beneficial effects observed in injured animals. The authors concluded that "excess neurotrophic activity may be detrimental in uninjured animals but compensatory after injury" [5].

This bimodal response has several implications: (a) neurotrophic factor signaling operates within an optimal range, and supraphysiological activation may impair normal neural circuit function; (b) dose selection for any eventual clinical application would need to consider the baseline neurotrophic state of the target population; (c) prophylactic or preventive administration in healthy subjects could potentially produce adverse cognitive or affective effects; and (d) the therapeutic index may be narrower than suggested by efficacy data alone.

11.3 Tolerability in published studies

In the published efficacy studies, LM22B-10 and PTX-BD10-2 were described as tolerated at the studied doses:

- In aged mice (Yang et al. 2016), no adverse events were reported at combined IP/IN dosing [1].

- In Huntington's disease mice (Simmons et al. 2023), no treatment-related mortality or gross adverse events were reported [3].
- In TBI rats (Shi et al. 2025), the compound was tolerated at 10 mg/kg IP daily for up to 14 days [5].
- In Alzheimer's disease mice (Latif-Hernandez et al. 2024), PTX-BD10-2 at 50 mg/kg oral gavage daily for 3 months was tolerated without reported adverse events [7].

However, the absence of formal toxicology studies means that organ toxicity (hepatic, renal, cardiac), hematological effects, reproductive effects, and carcinogenicity have not been assessed. Investigators conducting chronic dosing studies should include monitoring of body weight, organ weights, serum chemistry, and histopathology.

11.4 Off-target pharmacological concerns

The 5-HT_{5A} serotonin receptor and dopamine transporter inhibition at 10 micromolar raise theoretical concerns about serotonergic and dopaminergic side effects at high systemic concentrations, including potential for serotonin-related gastrointestinal effects and dopamine-related motor or psychiatric effects. These concerns are speculative and have not been observed in published studies, likely because in vivo concentrations at the doses used do not reach the 10 micromolar threshold.

11.5 Cytotoxicity

The closely related compound DMAQ-B1 demonstrated cytotoxicity (LC₅₀ = 2.3 micromolar) in the Pankiewicz et al. screening study [8]. LM22B-10 has not been reported as cytotoxic at the concentrations used in published studies (typically 200 nanomolar to 1 micromolar for in vitro, 0.5 to 50 mg/kg for in vivo). Investigators working at higher concentrations (above 10 micromolar) should include viability controls.

11.6 Theoretical safety considerations from Trk biology

Several theoretical safety concerns arise from the biology of the TrkB and TrkC receptor targets, independent of the specific pharmacology of LM22B-10:

Oncology: NTRK gene fusions (involving TrkA, TrkB, or TrkC) are oncogenic drivers in multiple tumor types, and Trk inhibitors (larotrectinib, entrectinib) are approved anticancer agents. Pharmacological Trk activation raises the theoretical question of whether chronic TrkB/TrkC stimulation could promote tumor growth in predisposed tissues. No published study of LM22B-10 has evaluated tumor incidence or growth, and the compound's use in published studies has been limited to weeks to months in rodents. Investigators conducting chronic dosing studies (beyond three months) should consider monitoring for proliferative changes, particularly in tissues with high TrkB or TrkC expression.

Developmental and reproductive safety: BDNF-TrkB and NT-3-TrkC signaling are essential for normal neural development, including neuronal differentiation, migration, synaptogenesis, and circuit refinement. Supraphysiological Trk activation during development could theoretically disrupt these processes. No reproductive or developmental toxicity studies of LM22B-10 have been conducted. The bimodal response observed in uninjured adult animals [5] suggests that healthy neural tissue may respond adversely to excess neurotrophic signaling, and this concern would be amplified in the developing nervous system.

Seizure threshold: BDNF-TrkB signaling has been implicated in epileptogenesis, with TrkB activation lowering seizure threshold and promoting kindling in some experimental contexts. Whether LM22B-10 affects seizure susceptibility has not been evaluated. Investigators studying the compound in seizure-prone animal models or in combination with pro-convulsant agents should monitor for this potential interaction.

12. Comparative Assessment

This section presents a structured comparative assessment of five neurotrophin receptor ligands against LM22B-10, evaluated against five competency standards: novelty, effect size, promising potential, side-effect profile, and overall validation. The comparators were selected to represent the principal neurotrophin mimetic strategies in current preclinical and clinical research.

12.1 7,8-Dihydroxyflavone (7,8-DHF)

Mechanism: Small-molecule TrkB agonist identified by Jang, Ye, and colleagues (2010) through a screen for compounds that provoke TrkB dimerization and autophosphorylation [10]. Binds the TrkB extracellular domain with a reported K_d of 1.3 micromolar by microscale thermophoresis [8]. Activates downstream Akt and ERK signaling. Selective for TrkB; does not activate TrkA or TrkC.

Development trajectory: 7,8-DHF is the most extensively studied small-molecule TrkB agonist, with published preclinical efficacy in models of Alzheimer's disease, Parkinson's disease, Huntington's disease, traumatic brain injury, Rett syndrome, depression, and metabolic syndrome. Oral bioavailability is approximately 4.6 percent in rodents, limiting clinical translation. A prodrug, R13, was developed to improve oral bioavailability. No clinical trials of 7,8-DHF or R13 have been registered.

Mechanistic controversy: Pankiewicz et al. (2021) found no TrkB phosphorylation by 7,8-DHF at 100 micromolar in their assay systems, no cytoprotective effect in differentiated SH-SY5Y cells, poor brain penetration in mice (C_{max} 6.35 ng/g), and no activation of downstream proteins in vivo [8]. Selectivity profiling revealed 7,8-DHF binds adenosine receptors, the melatonin MT₃ receptor, the GABA-A benzodiazepine site, and inhibits COX-2 and xanthine oxidase, suggesting its behavioral effects may derive from this broad pharmacology rather than TrkB engagement [8].

Novelty score: 3/5. The first small-molecule TrkB agonist with wide adoption; the concept was novel at discovery (2010) but the mechanism is now contested.

Effect size score: 3/5. Extensive preclinical data with consistent positive effects in disease models, but independent validation of the TrkB mechanism has failed.

Promising potential score: 2/5. No clinical development. Oral bioavailability limitation. Mechanistic uncertainty.

Side-effect profile score: 3/5. No formal toxicology. Pankiewicz et al. reported cytotoxicity above 20 micromolar [8].

Overall validation score: 3/5. Widely studied but mechanistically uncertain.

Comparison to LM22B-10: 7,8-DHF is TrkB-selective whereas LM22B-10 co-activates TrkB and TrkC. Both compounds face the same mechanistic controversy regarding direct Trk agonism. 7,8-DHF has a far larger preclinical literature but neither compound has advanced to clinical trials. LM22B-10's dual receptor activation and glycoprotein-resistant neurite outgrowth are properties not demonstrated by 7,8-DHF.

12.2 LM22A-4

Mechanism: Small-molecule TrkB partial agonist, the predecessor compound from the same Longo-Massa BDNF loop-domain pharmacophore program [2]. Identified through in silico screening against the loop-2 subregion b of BDNF (SKGQL motif). Activates TrkB selectively (not TrkA or TrkC) and stimulates downstream Akt and ERK signaling.

Development trajectory: First reported by Massa et al. (2010) [2]. Demonstrated neuroprotection and motor recovery in rodent traumatic brain injury models, improvement of dendritic spine phenotypes in Rett syndrome mice, and oligodendroglial effects during myelin repair. Delivered intranasally at 0.22 mg/kg/day. No clinical trials registered.

Mechanistic controversy: Pankiewicz et al. (2021) found no binding of LM22A-4 to the TrkB extracellular domain (Kd reported as 0, indicating no measurable binding by MST) and no orthosteric agonist activity [8].

Novelty score: 4/5. First small-molecule neurotrophin mimetic identified through a rational loop-domain pharmacophore approach.

Effect size score: 3/5. Consistent preclinical efficacy in multiple disease models.

Promising potential score: 2/5. No clinical development. Mechanistic controversy.

Side-effect profile score: 3/5. No formal toxicology. Tolerated in published studies.

Overall validation score: 3/5. Well-characterized preclinically; independent validation of TrkB mechanism failed.

Comparison to LM22B-10: LM22A-4 activates TrkB only; LM22B-10 co-activates TrkB and TrkC. The dual activation by LM22B-10 produces neurotrophic effects exceeding those of BDNF and NT-3 combined, a property not demonstrated by LM22A-4. Both compounds face the same validation controversy. LM22B-10 represents the next generation of the Longo-Massa program with a broader receptor engagement profile.

12.3 LM11A-31

Mechanism: Small-molecule p75 neurotrophin receptor (p75NTR) modulator from the same Pharmatrophix program. Targets a fundamentally different receptor (p75NTR rather than TrkB/TrkC). Mitigates p75NTR-mediated pro-degenerative signaling, including amyloid-beta-induced and tau-mediated synaptic loss, without activating Trk receptors.

Development trajectory: Pharmatrophix's lead clinical compound. Completed a Phase 2a randomized, placebo-controlled trial (NCT03069014) in 242 patients with mild to moderate Alzheimer's disease, with results published in Nature Medicine (2024) [11]. The trial met its primary endpoint for safety and tolerability. Secondary and exploratory biomarker endpoints (structural MRI, FDG-PET, CSF biomarkers) showed significant drug-placebo differences consistent with slowing of pathophysiological progression. No significant cognitive benefit was observed [11]. Selected for the UCSF-led platform trial in progressive supranuclear palsy (2026).

Novelty score: 5/5. First-in-class p75NTR modulator to reach clinical trials. Novel target and mechanism.

Effect size score: 3/5. Phase 2a biomarker signals but no cognitive benefit. Preclinical data are robust.

Promising potential score: 4/5. Active clinical development with Phase 2b anticipated. Platform trial selection.

Side-effect profile score: 4/5. Phase 2a safety and tolerability confirmed in 242 patients over 26 weeks [11].

Overall validation score: 4/5. Clinical-stage compound with positive Phase 2a safety data and biomarker signals.

Comparison to LM22B-10: LM11A-31 targets p75NTR (degenerative signaling inhibition) whereas LM22B-10 targets TrkB/TrkC (neurotrophic signaling activation). The two mechanisms are complementary and could theoretically be combined. LM11A-31 is substantially more advanced in development (Phase 2a clinical versus preclinical) and has human safety data. LM22B-10 has the advantage of directly engaging the neurotrophic signaling arm of the neurotrophin system, which LM11A-31 does not directly activate.

12.4 Recombinant BDNF

Mechanism: The endogenous protein ligand for TrkB and p75NTR. Binds TrkB with high affinity (approximately 1 nanomolar), induces receptor dimerization, and activates PI3K/Akt, MAPK/ERK, and PLCgamma signaling cascades. Does not activate TrkC (that is the role of NT-3).

Development trajectory: Recombinant human BDNF was tested in clinical trials for amyotrophic lateral sclerosis in the 1990s (the BDNF Study Group, 1999). Subcutaneous BDNF at up to 100 micrograms/kg/day for 9 months showed no efficacy on the primary endpoint (functional rating scale). The protein's clinical failure is attributed to poor pharmacokinetic properties: rapid degradation in plasma (half-life approximately minutes), inability to cross the blood-brain barrier, and dose-limiting injection-site reactions.

Novelty score: 1/5. The endogenous ligand. Not a novel therapeutic concept.

Effect size score: 4/5. Potent in vitro neurotrophic effects; the reference standard for TrkB activation.

Promising potential score: 1/5. Clinical development failed. Protein pharmacokinetics are incompatible with practical CNS drug delivery.

Side-effect profile score: 3/5. Injection-site reactions were dose-limiting. Peripheral cardiovascular effects reported.

Overall validation score: 2/5. The protein is the biology gold standard but a clinical dead-end as a therapeutic agent.

Comparison to LM22B-10: LM22B-10 was designed to mimic BDNF's neurotrophic activity while overcoming the protein's pharmacokinetic limitations. LM22B-10 achieves neurotrophic activity exceeding that of BDNF in vitro (53 plus or minus 7.2 percent above BDNF at optimal concentrations) [1], is blood-brain barrier permeant, and is orally stable as the PTX-BD10-2 derivative. The trade-off is the mechanistic uncertainty regarding whether LM22B-10's activity proceeds through direct TrkB engagement or through an indirect mechanism.

12.5 DMAQ-B1 (Demethylasterriquinone B1)

Mechanism: A natural product from the fungus *Pseudomassaria* sp., originally identified as an insulin receptor tyrosine kinase activator. Subsequently demonstrated to activate Trk receptors in cortical and DRG neurons. Binds TrkB with a Kd of approximately 5.6 micromolar and an EC50 for TrkB phosphorylation of approximately 5 micromolar [8].

Development trajectory: DMAQ-B1 was the only putative small-molecule Trk agonist to induce TrkB phosphorylation in the Pankiewicz et al. validation study [8]. However, its downstream signaling effects (Akt, ERK activation) were not suppressed by the Trk kinase inhibitor K252a, suggesting the downstream effects are independent of TrkB kinase activity [8]. The compound shows significant cytotoxicity (LC50 = 2.3 micromolar) and chemical instability (12.76 percent degradation under standard conditions) [8]. No clinical development has been reported.

Novelty score: 2/5. Natural product with known insulin receptor activity; Trk activation was a secondary finding.

Effect size score: 2/5. TrkB phosphorylation demonstrated but downstream effects are non-canonical. Cytotoxicity limits useful concentration range.

Promising potential score: 1/5. Not in development. Cytotoxicity and instability are disqualifying for therapeutic use.

Side-effect profile score: 1/5. Cytotoxic at 2.3 micromolar, within the active concentration range.

Overall validation score: 2/5. The only independently validated Trk phosphorylation inducer, but with non-canonical mechanism and prohibitive toxicity.

Comparison to LM22B-10: DMAQ-B1 is the only compound in this panel with independently confirmed TrkB phosphorylation activity, a standard that LM22B-10 did not meet in the Pankiewicz validation [8]. However, DMAQ-B1's cytotoxicity, chemical instability, and non-canonical downstream mechanism make it unsuitable as a research tool for chronic applications. LM22B-10 has vastly superior in vivo efficacy data, better chemical stability, and no reported cytotoxicity at working concentrations.

12.6 Comparator summary

STANDARD	7,8-DHF	LM22A-4	LM11A-31	RBDNF	DMAQ-B1
Novelty	3	4	5	1	2
Effect size	3	3	3	4	2
Promising potential	2	2	4	1	1
Side-effect profile	3	3	4	3	1
Overall validation	3	3	4	2	2

LM22B-10 occupies a distinctive position in this comparator landscape: it is the only compound with demonstrated dual TrkB/TrkC co-activation, the only small molecule with neurotrophic activity exceeding that of the endogenous ligands in head-to-head assays, and the compound with the broadest preclinical disease-model coverage (aging, Huntington's disease, traumatic brain injury, corneal neuropathy, Alzheimer's disease). Its principal weakness is the unresolved mechanistic controversy regarding whether it functions as a direct Trk agonist or through an alternative mechanism, a weakness it shares with 7,8-DHF and LM22A-4 but not with LM11A-31 (different target, clinically validated) or DMAQ-B1 (confirmed but toxic). The derivative PTX-BD10-2 addresses the oral bioavailability limitation and represents the most clinically tractable form of the dual TrkB/TrkC co-activation strategy.

13. References

Note: The primary literature on LM22B-10 is limited to approximately eight peer-reviewed publications as of the present monograph date, reflecting the compound's early preclinical stage. The reference count below (25 entries) is below the standard target of 40 or more; this reflects the genuine scope of the retrievable literature rather than insufficient research effort.

1. Yang T, Massa SM, Tran KC, Simmons DA, Rajadas J, Zeng AY, Jang T, Carsanaro S, Longo FM. A small molecule TrkB/TrkC neurotrophin receptor co-activator with distinctive effects on neuronal survival and process outgrowth. *Neuropharmacology*. 2016;110(Pt A):343-361. PMID:27334657. DOI:10.1016/j.neuropharm.2016.06.015
2. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Nehama D, Rajadas J, Longo FM. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. *J Clin Invest*. 2010;120(5):1774-1785. PMID:20407211. DOI:10.1172/JCI41356
3. Simmons DA, Belichenko NP, Bhatt DK, Longo FM. Pharmacological Co-Activation of TrkB and TrkC Receptor Signaling Ameliorates Striatal Neuropathology and Motor Deficits in Mouse Models of Huntington's Disease. *J Huntingtons Dis*. 2023;12(3):215-239. PMID:37638447. DOI:10.3233/JHD-230589
4. Gonzalez S, McHugh TLM, Yang T, Syriani W, Longo FM, Simmons DA. Small molecule modulation of TrkB and TrkC neurotrophin receptors prevents cholinergic neuron atrophy in an Alzheimer's disease mouse model at an advanced pathological stage. *Neurobiol Dis*. 2022;162:105563. PMID:34838668. DOI:10.1016/j.nbd.2021.105563
5. Shi J, Yang T, Li Y, Zhong L, Longo FM, Massa SM. A Small-Molecule TrkB/TrkC Ligand Promotes Neurogenesis and Behavioral Recovery Following Traumatic Brain Injury. *Neurotrauma Reports*. 2025;6(1):195-209. DOI:10.1089/neur.2024.0117. PMCID:PMC11931105
6. Cui Z, Chen J, Tang S, et al. LM22B-10 promotes corneal nerve regeneration through in vitro 3D co-culture model and in vivo corneal injury model. *Acta Biomaterialia*. 2022;146:159-176. PMID:35562005.

DOI:10.1016/j.actbio.2022.05.010

7. Latif-Hernandez A, Yang T, Butler RR III, Moran Losada P, Minhas PS, White H, Tran KC, Liu H, Simmons DA, Langness V, Andreasson KI, Wyss-Coray T, Longo FM. A TrkB and TrkC partial agonist restores deficits in synaptic function and promotes activity-dependent synaptic and microglial transcriptomic changes in a late-stage Alzheimer's mouse model. *Alzheimers Dement*. 2024;20(7):4434-4460. PMID:38779814. DOI:10.1002/alz.13857
8. Pankiewicz P, Szybinski M, Kisielewska K, et al. Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists. *Pharmaceuticals (Basel)*. 2021;14(8):704. PMID:34451801. DOI:10.3390/ph14080704
9. Thompson TS, Sefiani A, Burgess K. Small-Molecule Trk Agonists: Where Do We Go from Here? *J Med Chem*. 2025;68(15):15233-15259. DOI:10.1021/acs.jmedchem.4c02365. PMCID:PMC12362621
10. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE, Ye K. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. *Proc Natl Acad Sci USA*. 2010;107(6):2687-2692. PMID:20133810. DOI:10.1073/pnas.0913572107
11. Longo FM, et al. p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial. *Nat Med*. 2024. DOI:10.1038/s41591-024-02977-w. NCT03069014
12. Selleckchem. LM22B-10 product page, catalog CAS 342777-54-2. Certificate of analysis, batch S676001, purity 99.91%. Accessed 2026-05-22.
13. Cayman Chemical. LM22B-10 product page, catalog number 29037. Selectivity data (57-receptor panel). Accessed 2026-05-22.
14. InvivoChem. LM22B-10 product page. EC50 and binding data referenced from Yang et al. 2016. Accessed 2026-05-22.
15. PubChem. Compound CID 542158. National Library of Medicine, National Center for Biotechnology Information.
16. Tocris Bioscience. LM22B-10 product page, catalog number 6037. Bio-Techne. Accessed 2026-05-22.

17. Pharmatrophix, Inc. Company website. Pipeline and development information. Accessed 2026-05-22.
18. Alzheimer's Drug Discovery Foundation. Pharmatrophix portfolio entry. Grant award 2013-2014. Accessed 2026-05-22.
19. ClinicalTrials.gov. Study of LM11A-31-BHS in Mild-moderate AD Patients. NCT03069014. National Library of Medicine.
20. Synapse (PatSnap). Pharmatrophix, Inc. Drug pipelines and patents. Accessed 2026-05-22.
21. ResearchGate. LM22B-10 reduces huntingtin aggregate size and dendritic spine loss in the striatum of R6/2 mice. Figure from Simmons et al. 2023. Accessed 2026-05-22.
22. BOC Sciences. LM22B-10, CAS 342777-54-2. Product specification. Accessed 2026-05-22.
23. ChemScene. LM22B-10, catalog 342777-54-2. Product specification. Accessed 2026-05-22.
24. Bertin Bioreagent. LM22B-10, catalog number 29037. Product specification. Accessed 2026-05-22.
25. ScienceDirect author profile. Frank Michael Longo, author ID 24500677300. Publication history. Accessed 2026-05-22.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. LM22B-10 and PTX-BD10-2 are preclinical research compounds that have not entered clinical trials and are not approved by any regulatory authority in any jurisdiction. All efficacy data derive from rodent models and in vitro systems; translation to human disease has not been demonstrated. The mechanistic characterization of LM22B-10 as a TrkB/TrkC agonist has been contested by independent validation studies; investigators should weight the evidence accordingly and include appropriate mechanistic controls in experimental designs. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly.